ClinicalTrials.gg
WithdrawnNCT04369677Updated Feb 25, 2026

Thermoregulation Among Individuals With First-episode Psychosis

An observational study in Psychosis and First Episode Psychosis, sponsored by Nicholas Breitborde. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by Nicholas Breitborde · Observational

How we know

Why this study was withdrawn
lack of funding

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
0
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 759 studies in Psychotic Disorders with a site in United States — 97 open to participants now, 113 under way, 7 of them phase 3. Psychotic Disorders · United States.

Enrollment
65th of 67
0 · median 123
Started
2017
with 26 others
Observational
68 of 759
8 open now
Registered
581st of 759
by date

Among the 759 studies in Psychotic Disorders with a site in United States, this one is the 65th largest by enrollment of the 67 observational ones that give a count, is one of 27 that started in 2017, is one of 68 observational ones, and was the 581st registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

97 of the 759 studies in Psychotic Disorders with a site in United States are open now. Recruiting first, the newest first:

92 more — sign in →

All 97 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 759 studies in Psychotic Disorders with a site in United States, or all of them as a file.
02

Study summary

The project will evaluate thermoregulatory processes among individuals with and without first-episode psychosis.

Read the detailed description

The project will evaluate thermoregulatory processes among individuals with and without first-episode psychosis.

Aim 1: Assess whether individuals with first-episode psychosis have differences in mean temperature and diurnal temperature variation as compared to individuals without psychosis.

Aim 2: Examine whether mean temperature and temperature variation during periods of rest and activity are different between individuals with first-episode psychosis versus people without psychosis.

Aim 3: Explore the association between current core body temperature and current ratings of psychotic symptomatology among individuals with first-episode psychosis.

Study participants will complete baseline assessments (e.g., symptoms, functioning, and sleep) and then complete a 24-36 hour ambulatory assessment period in which core temperature, activity, sleep, and heart rate variability will be tracked continuously and symptom severity will be assessed sporadically using a symptom rating app on their smart phone. .Then they will complete a second study visit to repeat baseline assessments.

03

Conditions studied

  • Psychosis
  • First Episode Psychosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Eligibility for Individuals with First-Episode Psychosis:

  1. Diagnosis of a schizophrenia-spectrum disorder or mood disorder with psychotic features as determined using the Structured Clinical Interview for the DSM-5 .
  2. Less than 5 years since the onset of frank psychotic symptoms as determined using the Symptom Onset in Schizophrenia Inventory.
  3. No evidence of a pre-existing intellectual disability defined as a premorbid IQ >70 as estimated using the Reading subtest of the Wide Range Achievement Test-4.

Eligibility criteria

Eligibility for Individuals with First-Episode Psychosis:

  1. Diagnosis of a schizophrenia-spectrum disorder or mood disorder with psychotic features as determined using the Structured Clinical Interview for the .
  2. Less than 5 years since the onset of frank psychotic symptoms as determined using the Symptom Onset in Schizophrenia Inventory.
  3. No evidence of a pre-existing intellectual disability defined as a premorbid IQ >70 as estimated using the Reading subtest of the Wide Range Achievement Test-4.

Eligibility for Individuals without First-Episode Psychosis:

  1. No diagnosis of a schizophrenia-spectrum disorder or mood disorder with psychotic features as determined using the Structured Clinical Interview for the DSM-5.
  2. No evidence of a pre-existing intellectual disability defined as a premorbid IQ >70 as estimated using the Reading subtest of the Wide Range Achievement Test-4.

Eligibility for Individuals with and without First-Episode Psychosis:

  1. Ages 18 - 35
  2. No evidence of swallowing difficulties as assessed using the Swallowing Disturbance Questionnaire [SDQ]. defined as (i) a score \<5 on the SDQ oral phase questions, (ii) a score \<11.5 on the laryngopharygeal phase SDQ questions, and a total SDQ score \< 12.5.
  3. Not meeting diagnostic criteria for a substance use disorder over the past month as determined using the Structured Clinical Interview for the DSM-5 .
  4. No current or past diagnosis of a medical condition known to affect thermoregulatory Functioning as assessed using the Health Conditions that Affect Thermoregulation questionnaire
  5. Per recommendations from the manufacturer of the CorTemp continuous temperature sensor, we will not enroll:

    1. Individuals who weigh less than 80 pounds
    2. Individuals diagnosed with known or suspected obstructive diseases of the gastrointestinal tract
    3. Individuals with a history of gag reflex disorders or impairments
    4. Individuals with previous or scheduled gastrointestinal surgery
    5. Individuals having felinization of the esophagus
    6. Individuals with conditions that would result in hypomotility of the GI tract.
    7. Individuals scheduled to undergo Magnetic Resonance Imaging or Nuclear Magnetic Resonance in the next month
    8. Individuals with cardiac pacemaker or other implanted electric medical devices
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
0 participants (actual)
Patient registry
No

Groups and cohorts

  • First-Episode Psychosis

    Twenty individuals with FEP will complete a 24-hour continuous assessment of core body temperature using a CorTemp ingestible sensor (HQInc., Palmetto, FL).

  • Healthy

    Twenty age-matched individuals with no psychotic disorder will complete a 24-hour continuous assessment of core body temperature using a CorTemp ingestible sensor (HQInc., Palmetto, FL).

06

What researchers measure

Primary outcomes

  1. Differences in mean temperature and diurnal temperature variation

    Differences in mean temperature and diurnal temperature variation in individuals with first-episode psychosis as compared to individuals without psychosis.

    Time frame: 24 hour intervals

  2. Differences in mean temperature and temperature variation during periods of rest and activity

    Differences in mean temperature and temperature variation during periods of rest and activity between individuals with first-episode psychosis versus people without psychosis.

    Time frame: 24 hour intervals

  3. Association of core body temperature and ratings of psychotic symptomatology in FEP

    Association between core body temperature and ratings of psychotic symptomatology among individuals with first-episode psychosis.

    Time frame: 24 hour intervals

07

Study locations

1 site
  • Harding Hospital
    Columbus, Ohio 43210, United States
08

References and documents

Publications

  • Lu BY, Cullen CE, Eide CE, Williams CC, Apfeldorf WJ. Antidepressant-induced sweating alleviated by aripiprazole. J Clin Psychopharmacol. 2008 Dec;28(6):710-1. doi: 10.1097/JCP.0b013e31818d6b67. No abstract available. PubMed 19011447 ↗
  • Vybiral S, Jansky L. The role of dopaminergic pathways in thermoregulation in the rabbit. Neuropharmacology. 1989 Jan;28(1):15-20. doi: 10.1016/0028-3908(89)90061-0. PubMed 2927577 ↗
  • Heh CW, Herrera J, DeMet E, Potkin S, Costa J, Sramek J, Hazlett E, Buchsbaum MS. Neuroleptic-induced hypothermia associated with amelioration of psychosis in schizophrenia. Neuropsychopharmacology. 1988 May;1(2):149-56. doi: 10.1016/0893-133x(88)90006-1. PubMed 3251495 ↗
  • Rubinstein G. Schizophrenia, infection and temperature. An animal model for investigating their interrelationships. Schizophr Res. 1993 Aug;10(2):95-102. doi: 10.1016/0920-9964(93)90043-i. PubMed 8398951 ↗
  • Lkhagvasuren B, Nakamura Y, Oka T, Sudo N, Nakamura K. Social defeat stress induces hyperthermia through activation of thermoregulatory sympathetic premotor neurons in the medullary raphe region. Eur J Neurosci. 2011 Nov;34(9):1442-52. doi: 10.1111/j.1460-9568.2011.07863.x. Epub 2011 Oct 6. PubMed 21978215 ↗
  • Hayashida S, Oka T, Mera T, Tsuji S. Repeated social defeat stress induces chronic hyperthermia in rats. Physiol Behav. 2010 Aug 4;101(1):124-31. doi: 10.1016/j.physbeh.2010.04.027. Epub 2010 May 10. PubMed 20438740 ↗
  • Keeney AJ, Hogg S, Marsden CA. Alterations in core body temperature, locomotor activity, and corticosterone following acute and repeated social defeat of male NMRI mice. Physiol Behav. 2001 Sep 1-15;74(1-2):177-84. doi: 10.1016/s0031-9384(01)00541-8. PubMed 11564466 ↗
  • Radonjic NV, Petronijevic ND, Vuckovic SM, Prostran MS, Nesic ZI, Todorovic VR, Paunovic VR. Baseline temperature in an animal model of schizophrenia: long-term effects of perinatal phencyclidine administration. Physiol Behav. 2008 Feb 27;93(3):437-43. doi: 10.1016/j.physbeh.2007.10.003. Epub 2007 Oct 10. PubMed 17996259 ↗
  • Horvath G, Kekesi G, Petrovszki Z, Benedek G. Abnormal Motor Activity and Thermoregulation in a Schizophrenia Rat Model for Translational Science. PLoS One. 2015 Dec 2;10(12):e0143751. doi: 10.1371/journal.pone.0143751. eCollection 2015. PubMed 26629908 ↗
  • Chong TW, Castle DJ. Layer upon layer: thermoregulation in schizophrenia. Schizophr Res. 2004 Aug 1;69(2-3):149-57. doi: 10.1016/s0920-9964(03)00222-6. PubMed 15469188 ↗
  • Arnold VK, Rosenthal TL, Dupont RT, Hilliard D. Redundant clothing: a readily observable marker for schizophrenia in the psychiatric emergency room population. J Behav Ther Exp Psychiatry. 1993 Mar;24(1):45-7. doi: 10.1016/0005-7916(93)90007-j. PubMed 8370796 ↗
  • Shiloh R, Schapir L, Bar-Ziv D, Stryjer R, Konas S, Louis R, Hermesh H, Munitz H, Weizman A, Valevski A. Association between corneal temperature and mental status of treatment-resistant schizophrenia inpatients. Eur Neuropsychopharmacol. 2009 Sep;19(9):654-8. doi: 10.1016/j.euroneuro.2009.04.010. Epub 2009 Jun 2. PubMed 19493658 ↗
  • Mazerolle SM, Ganio MS, Casa DJ, Vingren J, Klau J. Is oral temperature an accurate measurement of deep body temperature? A systematic review. J Athl Train. 2011 Sep-Oct;46(5):566-73. doi: 10.4085/1062-6050-46.5.566. PubMed 22488144 ↗
  • Palmier-Claus JE, Ainsworth J, Machin M, Barrowclough C, Dunn G, Barkus E, Rogers A, Wykes T, Kapur S, Buchan I, Salter E, Lewis SW. The feasibility and validity of ambulatory self-report of psychotic symptoms using a smartphone software application. BMC Psychiatry. 2012 Oct 17;12:172. doi: 10.1186/1471-244X-12-172. PubMed 23075387 ↗
  • First, M.B., et al., Structured Clinical Interview for DSM-5-Research Version2015, Arlington, VA: American Psychiatric Association.
  • Perkins DO, Leserman J, Jarskog LF, Graham K, Kazmer J, Lieberman JA. Characterizing and dating the onset of symptoms in psychotic illness: the Symptom Onset in Schizophrenia (SOS) inventory. Schizophr Res. 2000 Jul 7;44(1):1-10. doi: 10.1016/s0920-9964(99)00161-9. PubMed 10867307 ↗
  • Wilkinson, G.S. and G.J. Robertson, Wide Range Achievement Test (WRAT4)2006, Lutz, FL: PAR, Inc
  • Manor Y, Giladi N, Cohen A, Fliss DM, Cohen JT. Validation of a swallowing disturbance questionnaire for detecting dysphagia in patients with Parkinson's disease. Mov Disord. 2007 Oct 15;22(13):1917-21. doi: 10.1002/mds.21625. PubMed 17588237 ↗
  • Cohen JT, Manor Y. Swallowing disturbance questionnaire for detecting dysphagia. Laryngoscope. 2011 Jul;121(7):1383-7. doi: 10.1002/lary.21839. Epub 2011 Jun 10. PubMed 21671239 ↗
  • Cheshire WP Jr. Thermoregulatory disorders and illness related to heat and cold stress. Auton Neurosci. 2016 Apr;196:91-104. doi: 10.1016/j.autneu.2016.01.001. Epub 2016 Jan 6. PubMed 26794588 ↗
  • Auther, A., C. Smith, and B. Cornblatt, Global Functioning: Social Scale (GF: Social). Glen Oaks, NY: Zucker-Hillside Hospital, 2006.
  • Niendam, T., et al., Global Functioning: Role Scale (GF: Role). Los Angeles, CA: University of California, Los Angeles, 2006.
  • Hays, R.D., S. Prince-Embury, and H.Y. Chen, RAND-36 Health Status Inventory1998, San Antonio, TX: The Psychological Corporation.
  • Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4. PubMed 2748771 ↗
  • Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76. doi: 10.1093/schbul/13.2.261. PubMed 3616518 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2017 (actual). Primary completion is estimated for Apr 2025, 98 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2020
First posted
Apr 30, 2020
StartActual
Jan 17, 2017
Primary completionEst.
Apr 3, 2025
CompletionEst.
Apr 3, 2025
Last update
Feb 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04369677
Lead sponsor
Nicholas Breitborde
Responsible party
Nicholas Breitborde (Associate Professor, Ohio State University) — Sponsor-investigator
First posted
Apr 30, 2020
Start date
Jan 17, 2017
Primary completion
Apr 3, 2025 (estimated)
Completion
Apr 3, 2025 (estimated)
Last update
Feb 25, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion